Free Trial

Abeona Therapeutics Q1 2023 Earnings Report

Abeona Therapeutics logo
$5.98 -0.02 (-0.33%)
As of 11:33 AM Eastern

Abeona Therapeutics EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Abeona Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Abeona Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Abeona Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Abeona Therapeutics Reports Q3 2024 Financial Highlights
See More Abeona Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Abeona Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abeona Therapeutics and other key companies, straight to your email.

About Abeona Therapeutics

Abeona Therapeutics (NASDAQ:ABEO)., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

View Abeona Therapeutics Profile

More Earnings Resources from MarketBeat